Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 4;13(9):1767.
doi: 10.3390/v13091767.

Treatments for HBV: A Glimpse into the Future

Alessandra Bartoli  1   2 , Filippo Gabrielli  1   3 , Andrea Tassi  1   3 , Carmela Cursaro  1 , Ambra Pinelli  1   2 , Pietro Andreone  1   2
Affiliations
Review

Treatments for HBV: A Glimpse into the Future

Alessandra Bartoli et al. Viruses. .

Abstract

The hepatitis B virus is responsible for most of the chronic liver disease and liver cancer worldwide. As actual therapeutic strategies have had little success in eradicating the virus from hepatocytes, and as lifelong treatment is often required, new drugs targeting the various phases of the hepatitis B virus (HBV) lifecycle are currently under investigation. In this review, we provide an overview of potential future treatments for HBV.

Keywords: HBV; direct antiviral agents; gene therapy; immunotherapy; therapeutic vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The replicative cycle of hepatitis B virus (HBV). Details about the various phases of this process are described in the text. HBV: hepatitis B virus; EGFR: epithelial growth factor receptor; NTCP: sodium/taurocholate cotransporting polypeptide; rcDNA: relaxed circular deoxyribonucleic acid; cccDNA: covalently closed circular DNA; HBV RNAs: HBV ribonucleic acids; Pol: viral polymerase; HBx: hepatitis B protein x; HBc: hepatitis B core protein; HBeAg: hepatitis B E antigen; HBsAg: hepatitis B surface antigen; SVP: small vesicle particle.
See this image and copyright information in PMC

References

    1. WHO|Global Hepatitis Report. 2017. [(accessed on 30 March 2021)]. Available online: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
    1. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995;13:29–60. doi: 10.1146/annurev.iy.13.040195.000333. - DOI - PubMed
    1. Grossi G., Viganò M., Loglio A., Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs) Liver Int. 2017;37((Suppl. S1)):45–51. doi: 10.1111/liv.13291. - DOI - PubMed
    1. Revill P.A., Chisari F.V., Block J.M., Dandri M., Gehring A.J., Guo H., Hu J., Kramvis A., Lampertico P., Janssen H.L.A., et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 2019;4:545–558. doi: 10.1016/S2468-1253(19)30119-0. - DOI - PMC - PubMed
    1. Ni Y., Lempp F.A., Mehrle S., Nkongolo S., Kaufman C., Fälth M., Stindt J., Königer C., Nassal M., Kubitz R., et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146:1070–1083. doi: 10.1053/j.gastro.2013.12.024. - DOI - PubMed